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INTRODUCTION
Ovarian cancer has the highest mortality rate
among all the gynecologic cancers, being the 7th
most common cancer in the United States, repre-
senting 3% of cancer malignancy to date, and con-
tributing to 6% of the mortality rate due to cancer
in women. Epithelial ovarian cancer represents 90-
95% of all ovarian cancer. They occur in all ages,
but have a higher incidence in older patients. Ova-
rian cancer incidence in women aged 40-44 years
old is 15.7 every 100,000, inclining to 54 every
100,000 in women aged 75-79 years old.1-3
In South East Asia, including Indonesia, ovarian
cancer incidence is 5.2%. Record of new cases of
ovarian cancer for 3 years at the Histopathology
Unit of Sriwijaya University at Dr. Mohammad
Hoesin Hospital Palembang stated that ovarian
cancer incidence in 2006 constitutes 12% of all
cancers, with a decline to 7%, and rebounding to
10% in 2008, which represents a third of all ma-
lignancies.2-5
The important risk factor for ovarian cancer is
family history of breast or ovarian cancer, where
about 5-10% of patients have a predisposing ge-
netic factor.2 Hereditary Breast and Ovarian Cancer
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Abstrak
Tujuan: Untuk mengetahui adanya hubungan polimorfisme genBRCA1 Q356R (1186A=G) dengan kejadian karsinoma ovarium
epitelial.
Metode: Penelitian ini merupakan studi observasional analitik dengan
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Syndrome (HBOC) is an inherited cancer prone
syndrome. The hallmark of this syndrome is more
than one family member with breast or ovarian
cancer, or both, one family member having both,
and one family member having breast cancer in a
very young age. Germline mutation of BRCA1 and
BRCA2 is the culprit and main cause of most HBOC,
even though an individual with one defective allele
in BRCA1 or BRCA2 from maternal or paternal ori-
gin had a second functional allele, and even when
this second allele becomes non-functional, cancer
can still develop through accumulation of other
mutations.6
Some studies have stated that polymorphism in
other genes can change the penetration of BRCA1
and BRCA2 for ovarian cancer.3 The risk of ovarian
cancer is higher in BRCA1 carriers. Therefore, the
functional polymorphism in BRCA1 is considered
to be more likely to influence the occurrence of
ovarian cancer compared to BRCA2. There are 10
polymorphisms in BRCA1 with allele frequency
>5% in caucasians. Nevertheless, only 5 polymor-
phisms provoke the substitution of amino acid,
which are Q356R (1186A=G), P781L (2731T=C),
E1038G (3232A=G), K1183R (3667A=G) and
S1613G (4956A=G). These polymorphisms, with
the exception of Q356R (1186A=G), are in signifi-
cant linkage disequilibrium, and the effects of all of
these on ovarian cancer can be ascertained by con-
sidering only the Q356R (1186A=G).7,8
Anton-Culver et al carried out a population
based study about the variants of BRCA1 sequence,
and concluded that there is a significant correlation
between BRCA1 mutation with cancer patients
having a family history of ovarian cancer. Janezic
et al described the distribution of 91 polymor-
phism cases in Caucasians, a rare form of Q356R
polymorphism (1186A=G) where the rare 1186G
allele of Q356R (1186A=G) polymorphism has a
higher frequency, and associated with family his-
tory of ovarian cancer (p=0.003). It shows that this
polymorphism affects the occurrence of ovarian
cancer. Wenham RM et al reported BRCA1 Q356R
gene polymorphism provides the odd ratio of 1.9
to the occurence of ovarian cancer.7-9
Most studies on BRCA1 focused only on Cauca-
sian populations. However, allele frequency from
the gene with higher penetration to ovarian cancer
in the Asian population is possibly higher than Cau-
casian population. Asian immigrant women, espe-
cially from South Asia who lived in western coun-
tries showed a higher incidence of ovarian and
breast cancer. Risch et al reported a higher muta-
tion frequency of ovarian cancer in Indo-Pakistani
descent than North-West European or British de-
scent who lived in Ontario, Canada.10
The contribution of BRCA1 mutation towards in-
cidence of epithelial ovarian cancer in Asian popu-
lation, especially in Indonesia has not been eluci-
dated yet. Based on this reason, this study needs
to be done. This study focuses on polymorphism of
BRCA1 gene at the Q356R (1186=G) position.
METHODS
This study is an observational-analytic study with
case-control study design which was done from
September 2013 until March 2014 at Dr. Moham-
mad Hoesin Hospital in Palembang.
The subjects were divided into two groups, a
case group with patients who have been diagnosed
with epithelial ovarian cancer based on surgical
and histopathologic findings (n=50), and a control
group with patients who have not been diagnosed
with malignancy (n=50). Subjects who met the cri-
teria was given explanation about the study proce-
dures and the study benefit. Subjects who agreed,
signed the informed consent and had blood samp-
les drawn.
The extraction method of DNA Chelex-100 used
Phosphate Buffer Saline (PBS) pH 7.4; Safonin
0.5% on PBS; and Chelex 20% on dd H2O pH 10.5.
PCR was performed using the forward primer 5’-
GGA CTC CCA GCA CAG AAA AA-3’ and reverse
primer 5’-TCC CCA TCA TGT GAG TCA TC-3’. The
reaction was conducted in a final volume of 15 μl
containing 0.5 ng/μl genomic DNA, 0.5 nmol/l for-
ward primer, 0.5 nmol/l reverse primer, 0.2
mmol/l deoxynucleotide triphosphate (dNTP), 1.5
mmol/l MgCl2. PCR buffer, and 0.025 units/μl Taq
DNA polymerase. PCR conditions consisted of an
initial denaturation step at 95°C for 3 minutes, 30
cycles of 94°C for 45 seconds, 57°C for 45 seconds,
and 72°C for 1 minute; an extension step at 72°C
for 10 minutes, then at 4°C until digested. A digest
of the amplicon was performed by combining 15
μl of the PCR amplification product, 2 μl Buffer and
10 units of AluNI enzyme in a final volume of 20
μl. Samples were incubated at 37°C for 4.5 hours,
and analyzed immediately on a 2% agarose gel.
The undigested arginine (R) allele can be seen as
a band at 211 bp, whereas the glutamine (Q) allele
Vol 3, No 4
October 2015 BRCA1 Gene Q356R polymorphism  207
|
is represented by the digestion products at 134
and 77 bp.
Electrophoresis and visualisation was done on
agarose gel made using 2 grams of agarose in Er-
lenmeyer glass with 40 ml buffer TAE added in.
The mixture is mixed and heated until boiling point
and then 4 μl of ethidium bromide was added. So-
lution was chilled in a mold for 30 minutes. Five μl
PCR product was mixed with long buffer and was
added to an electrophoresis device, which was set
on 75 mV voltage, 350 A for 30 minutes. Visuali-
zation was performed using ultraviolet light with
Gel-Doc made by BIO-RAD Laboratories USA, con-
nected to a computer, and the visualisation result
was analyzed using Quantity one software pro-
gramme.
RESULTS
There were 50 women with epithelial ovarian can-
cer in the case group and 50 normal women or
non-malignancy diagnosis in the control group.
Subject characteristics can be seen in Table 1.




n % n %
Age
10 - 20 1 2.0 4 8.0
21 - 30 5 10.0 23 46.0
31 - 40 10 20.0 16 32.0 0.001
41 - 50 17 34.0 5 10.0
51 - 60 16 32.0 1 2.0
>60 1 2.0 1 2.0
Ethnic group
Sumateran 49 98.0 47 94.0 0.617
Javanese 1 2.0 3 6.0
Education
Elementary 13 26.0 7 14.0
Junior High School 5 10.0 2 4.0 0.144
Senior High School 26 32.0 37 64.0
Graduate 6 12.0 4 8.0
Job
Midwife 43 86.0 45 90.0
Merchant 0 4.0 1 2.0
Student 1 2.0 0 0 0.532
Farmer 1 2.0 0 0
Civil servant 5 10.0 4 8.0
History of contraception
Hormonal 17 34.0 25 50.0
Non-hormonal 0 0 1 2.0 0.139
None 33 66.0 24 48.0
Family history of ovarian cancer
Yes 17 34.0 9 18.0 0.068
No 33 66.0 41 82.0
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Table 1 demonstrated that there was no signifi-
cant difference in terms of subject characteristics
based on ethnic group, education, job, history of
hormonal contraception, and family history of
ovarian cancer between case group and control
group, with p value of 0.617, 0.144, 0.532, 0.139
and 0.068, respectively. Only age showed a signifi-
cant difference between the case and control group
with p=0.001.
Based on surgical and histopathology result in
the case group, the most common stage of epi-
thelial ovarian cancer was stage IIIC and IIIB which
constitutes 36% and 18% of the cases. For the re-
maining cases, the proportion were 2-10%. The
complete result of epithelial ovarian cancer staging
is presented in Table 2.






Inadequate staging 6 12.0
stadium I A 4 8.0
stadium I C 5 10.0
stadium II A 2 4.0
stadium II C 1 2.0
stadium III A 3 6.0
stadium III B 9 18.0
stadium III C 18 36.0
stadium IV 2 4.0
Total 50 100.0
BRCA1 Q356R (1186A=G) Genotype
Examination result with PCR-RFLP (Polymerase
Chain Reaction - Restriction Fragment Length Poly-
morphism) method showed all of the subjects in
both groups have a wild type-normal genotype
(QQ) of BRCA1 Q356R (1186A=G). There was no
heterozygote genotype (QR) of BRCA1 Q356R
(1186A=G) or mutant-homozygote (RR). Thus,
there was no significant difference in the genotype
of BRCA1 Q356R (1186A=G) between the case
group and control group (p=0.999).
BRCA1 Q356R (1186A=G) allele on both case
group and control group is Q. Thus, there was no
significant difference in regards to BRCA1 Q356R
(1186A=G) allele between case group and control
group (p=0.999).
BRCA1  Polymorphism  Relationship  with
Ephitelial Ovarian Cancer Incidence
To assess the polymorphism, we performed allele
analysis with PCR-RFLP method. The results of this
study showed no polymorphism discovery in the
case group and the control group, indicating the
absence of changes in codon 356 of glutamine (Q)
amino acid to arginine (R) amino acid. In this study,
the case or control groups amplicon digested on
211 bp, which means that the nucleotide was a
wild type-normal or glutamine amino acid (Q) on
codon 356. Polymorphism of BRCA1 (1186A=G)
was not found in this study, which can be seen as
that there was no digested amplicon on 134 bp and
77 bp or arginine amino acid (R) on codon 356.
The PCR-RFLP result is shown on picture 1, for
case sample number 1 to 4 (KS1 - KS4 ) and control
number 1 to 4 (KT1 - KT4).
This proves that there was no variation of more
than one phenotype that was genetically caused by
the allele differences. Based on Fisher’s exact test,
there was no significant correlation between poly-
morphism of BRCA1 and ephitelial ovarian cancer
incidence (p=0.999).
DISCUSSION
BRCA1 is a tumor supressor gene that will inhibit
cellular function process and will lose its function
when it is mutated. Growth factor causes cell
growth, and if the growth noted by the body is ade-
quate, then the growth suppression factor will be
activated until homeostasis is achieved. If a muta-
Figure 1. PCR-RFLP Result for Sample Case no 1-4 (KS1-
KS4) and Control Case no 1-4 (KT1- KT4)
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tion occurred to this gene, the suppression process
can not be done, and genomic instability will occur,
which will ultimately lead to cancer.
The highest age distribution of ephitelial ovarian
cancer patients in this study was 41-50 years old
(34%) and the most common parity status was
multipara (36%). This number was similar to a
study by Wenham RM et al, which reported epi-
thelial ovarian cancer to be encountered mostly in
the age group of 20-50 years old (50%), and in the
multiparous group (51%).7 Several former studies
have stated that ovarian cancer could occur in all
age groups and that the incidence increases with
age.1-3
Based on ethnicity, the Sumateran ethnic group
makes up the largest proportion in both groups in
our study, which is 98% in the case group and 94%
in the control group. This is because the study was
held in South Sumatera province, specifically in
Palembang.
History of ovarian cancer in the family in the
case group was 34%, which was higher than in the
control group (18%). Menopause was more com-
monly found in the case group, which was 36%,
compared to 4% in the control group. Schorge JO
stated that risk factor of ovarian cancer that gave
the most contribution to ovarian cancer incidence
is family history of ovarian cancer, where 5-10%
patients have an inherited genetic predisposition.2
The most commonly used method of contraception
was hormonal contraception in the case group
(34%) and also in the control group (50%). Center
of Disease Control (CDC) have stated that there is
a decreased risk of ovarian cancer as much as 40%
in women aged 20-24 years old who used oral con-
traceptives, with a relative risk of 0.6.7 Other stu-
dies reported that oral contraceptive use for one
year, decreases the risk by 11%. Meanwhile, the
use of oral contraceptives for five years decreases
the risk until 50%. The decreasing risk gets more
significant with longer use.11-13
Ovarian cancer diagnosis in our study showed
that many patients with epithelial ovarian cancer
was diagnosed in the late stage, which is stage IIIC
(36%) and IIIB (18%). This is caused by the fact
that ovarian cancer is often asymptomatic and
there is no effective screening method for ovarian
cancer, so that 70% of cases are found in the late
stage, and metastatic tumor have extended oustide
the ovary.13
Our study showed that there was no significant
relation of BRCA1 Q356 R (1186A=G) polymor-
phism with the incidence of epithelial ovarian can-
cer (p>0.05). The examination with PCR-RFLP
showed that there was no variation of more than
one phenotype that was genetically caused by the
allele differences. This was proven by the absence
of polymorphism at base pair 1186 from adenine
nucleotide (A) into guanine (G); or glutamine (Q)
on amino acid position 356 which is digested on
211 bp into arginine (R) which will be digested on
134 bp and 77 bp. Finally, there was no QR (hete-
rozygote) genotype and RR (mutant-homozygote)
genotype on BRCA1 Q356R (1186A=G) gene.
This result was concordant with a study by
Wenham et al, who reported that BRCA1 Q356R
gene has no correlation with risk of ovarian cancer.
Their study stated that the frequency of heterozy-
gote and homozygote from R allele is 9% and <1%
in ovarian cancer cases, and in controls being 10%
and <1%, respectively.7
Thus, the occurence of ovarian cancer in our
study did not occur on DNA level, but it could occur
due to epigenetic process. Epigenetic is a pheno-
type status change which is not based on the geno-
type changes, in other words there are gene ex-
pression changes that are not caused by changes
in the DNA sequence. DNA mutations lead to
changes in DNA sequence and irreversible gene ex-
pression. This epigenetic process is potentially re-
versible, but remains stable during cell differentia-
tion so that this epigenetic changing can be inherit-
ed to children at cell differentiation.14 According to
Kwon, besides mutation the inactivation of BRCA1
as a tumor suppressor gene is related to hyper-
methylation of DNA on CpG islands. Transcrip-
tional inactivation of tumor suppressor genes by
DNA promoter hypermethylation on BRCA1 CpG
island is one of the mechanism leading to develop-
ment of tumor on ovarian cancer cells.15
Anton-Culver et al summarized that there was a
significant correlation between the BRCA1 muta-
tion with ovarian cancer cases with family history
of ovarian cancer. Janezic et al found that a
common polymorphism was determined in 91
Caucasian cancer cases. A rare form of polymor-
phism, Q356R (1186G), was significantly asso-
ciated with a family history of ovarian cancer
(p=0.03), suggesting that this polymorphism af-
fects the occurence of ovarian cancer. In our study,
there is no evidence of family history of ovarian
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cancer being related to epithelial ovarian cancer
incidence (p=0.068). This was thought to be caused
by the difference of race, where in our study we
involved the Indo-China race; meanwhile the An-
ton-Culver study was involving non-Hispanic white
population, and Janezic et al involved Caucasians.
On this study, DNA sequencing was not done. It
was based on PCR-RFLP result using AluN1 en-
zyme, that showed no polymorphism on both case
and control groups. AluN1 enzyme specifically di-
gests the nucleotide adenine (A) and guanine (G)
on glutamine amino acid (Q) and arginine (R),
allowing for nucleotides A or G to be identified pre-
cisely.
CONCLUSION
We can conclude that BRCA1 Q356R (1186A=G)
genotype on the epithelial ovarian cancer cases and
controls was QQ (wild type-normal). Meanwhile,
the allele of gene BRCA1 q356R (1186A=G) in epi-
thelial ovarian cancer patients as well as in controls
was Q. There was no significant association be-
tween BRCA1 polymorphism with epithelial ovar-
ian cancer incidence.
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